P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo.
Makoto Hamasaki,Teru Hideshima,Pierfrancesco Tassone,Paola Neri,Kenji Ishitsuka,Hiroshi Yasui,Norihiko Shiraishi,Noopur Raje,Shaji Kumar,Donald Picker,GS Jacob,Paul G. Richardson,Nikhil C. Munshi,Kenneth C. Anderson +13 more
TL;DR: It is shown that azaspirane both induces MM cell apoptosis and inhibits cytokine secretion in the BM milieu, providing the framework for clinical trials to improve patient outcome in MM.
Journal ArticleDOI
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
Jian Hou,Jie Jin,Yan Xu,Depei Wu,Xiaoyan Ke,Daobin Zhou,Jin Lu,Xin Du,Xie-Qun Chen,Junmin Li,Jing Liu,Neeraj Gupta,Michael J. Hanley,Hongmei Li,Zhaowei Hua,Bingxia Wang,Xiaoquan Zhang,Hui Wang,Helgi van de Velde,Paul G. Richardson,Philippe Moreau +20 more
TL;DR: This study demonstrated that PFS and OS were significantly improved with ixazomib-Rd versus placebo-RD, with limited additional toxicity, in patients with RRMM.
Journal ArticleDOI
Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial
Hervé Avet-Loiseau,Jill Corre,Valérie Lauwers-Cances,Marie-Lorraine Chretien,Nelly Robillard,Xavier Leleu,Cyrille Hulin,Catherine Gentil,Bertrand Arnulf,Karim Belhadj,Sabine Brechignac,Laurent Garderet,Lionel Karlin,Gerald Marit,Lotfi Benboubker,Frédérique Orsini-Piocelle,Bruno Royer,Bernard Drenou,Mourad Tiab,Thierry Lamy,Margaret Macro,Paul G. Richardson,Kenneth C. Anderson,Malek Faham,Thierry Facon,Philippe Moreau,Michel Attal,Nikhil C. Munshi +27 more
TL;DR: This poster presents a poster presented at the 2015 Annual Meeting of the American-Society-of-Hematology entitled “Advances in Hematology: Towards a poster-gauging future generation of Hematological Assisted Decision-Making Machines”.
Journal ArticleDOI
A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results.
Andrew Spencer,Simon J. Harrison,Simon J. Harrison,Jeffrey A. Zonder,Ashraf Z. Badros,Jacob P. Laubach,Krystal Bergin,Amit Khot,Todd M. Zimmerman,Dharminder Chauhan,Nancy Levin,Ann MacLaren,Steven D. Reich,Mohit Trikha,Paul G. Richardson +14 more
TL;DR: PMD was well tolerated and demonstrated promising activity in heavily pre‐treated, high‐risk RRMM patients and was determined to be the RP2D.
Journal ArticleDOI
Fluorination methods for drug discovery and development.
TL;DR: This review highlights the importance of fluorinated compounds in drug discovery, and provides an overview on the synthetic strategies and methodologies developed to access them both in discovery and development, as well as investigating the extension of these methods for PET-labelling.